Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

What is the optimal treatment for a locally advanced rectal cancer on the anterior wall abutting the prostate in a medically inoperable patient with a remote history of LDR brachytherapy for low risk prostate cancer?

1
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would start with chemotherapy if that is an option and tailor RT dose to some extent based on response. If there is great response even local excision can be evaluated? Rectal and urethral complications are high and I have seen patients developing these complications even with 45 to 50.4 Gy preop ...

Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Langerhans cell histiocytosis (LCH) is a clonal proliferation of Langerhans cells (dendritic cells), part of the mononuclear-phagocytic system. Some patients present with unifocal disease, often in bone. A variety of treatments are acceptable for unifocal disease, including radiation therapy. Very l...

Which imaging modalities and schedule do you use to follow stage I-II follicular lymphoma that was treated with radiotherapy alone?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Colorado School of Medicine

PET has been demonstrated to be more sensitive and specific in staging for FL as well as a strong independent predictor of outcome after treatment. Patients also have ~50% risk of developing recurrence outside the RT volume - and PET allows for whole-body imaging. PET is therefore the imaging modali...

Does the presence of interstitial lung disease (excluding IPF) affect your decision to offer conventional fractionated RT for Stage III NSCLC?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Toronto

Tough question. I think a key step would be how certain the diagnosis of ILD is. I.e., was this a comment incidentally on a CT scan from radiology, or does the patient have active ILD management by a pulmonologist? Certainly, UIP patients appear to have higher rates of severe toxicity following RT. ...

How do you decide timing of adjuvant radiation with respect to chemotherapy for a patient with resected pancreatic adenocarcinoma with microscopic positive margins?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

Level 1 evidence supports chemotherapy, FOLFIRINOX is the standard. The benefit of radiation is modest in comparison and based on post-hoc analysis of phase III trials (ESPAC-1, and others that are themselves nearly uninterpretable). The answer to this question is chemotherapy followed by restaging ...

Would you offer adjuvant radiation in addition to chemotherapy for a patient with stage IIIC uterine carcinosarcoma with cervical involvement?

2
2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

This is a hard situation as there is no clear data for the exact treatment plan. For surgically staged patients with stage IIIC uterine cancer our tumor board treatment plans typically include discussion of PORTEC-3 (de Boer et al., PMID 31345626) and GOG-258 (Matei et al., PMID 31189035). Patients ...

For locally advanced rectal cancer, will the recent update of RAPIDO lead you to change your practice when approaching TNT?

9
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

We prefer long course chemoradiation followed by consolidation with FOLFOX and non-operative management based on the OPRA trial, which reported 60% versus 40% using this sequence versus initial chemotherapy.

How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology

Summary: This is a challenging clinical scenario, and one in which I think there is currently a lot of practice variability. In such cases, I would not jump to action immediately, and I would first try to obtain some additional information. This would include repeat PSA for confirmation as well as f...

How soon after SpaceOAR placement can radiation planning CT be performed?

3
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Utah School of Medicine

At Univ of Utah, we serve a geographic footprint equivalent to 20% of the United States. As such, many patients travel from 100s of miles away from therapy at our center. We put in spacers, and perform CT simulation on the same day (usually 2 hours apart). Never noticed any significant issues with d...

How do you manage prostate cancer in patients that cannot swallow pills?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · VCU Massey Comprehensive Cancer Center

The only one suitable for feeding tube administration is apalutamide (must be 8 French or greater feeding tube size). My oncology pharmacist suggests tablet(s) can be placed in a syringe (whole, not crushed), distilled water then added, shaken vigorously to disperse contents, administered through...